Compare JMIA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | FTRE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.0M | 829.3M |
| IPO Year | 2018 | 2023 |
| Metric | JMIA | FTRE |
|---|---|---|
| Price | $7.17 | $9.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $16.75 | $14.06 |
| AVG Volume (30 Days) | ★ 2.1M | 913.0K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $22.18 | N/A |
| Revenue Next Year | $23.26 | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $2.13 | $3.97 |
| 52 Week High | $14.72 | $18.67 |
| Indicator | JMIA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 46.21 |
| Support Level | $6.58 | $9.56 |
| Resistance Level | $8.43 | $10.47 |
| Average True Range (ATR) | 0.47 | 0.63 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 31.64 | 39.04 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.